All our kits are based on the novel, proprietary Naveni™ Proximity Ligation Technology, which enables precise detection of proteins, protein-protein interactions, or protein modifications in cultured cells fresh-frozen and FFPE samples. The flexible in situ kits contain secondary detection reagents called Navenibodies. The Navenibodies can be used with one or two primary IgG antibodies.
Target-specific products – primary antibody system included
Our target-specific kits are based on the proprietary Naveni™ Proximity Ligation Technology, including carefully selected and validated Navenibodies with specific target protein detection. No extra antibodies are needed; the assay is already optimized.
Custom solutions to fit your research needs
Do you have specific research questions, or do you need help with a target-specific assay? Please get in touch with us; we have additional support and services to suit your research project’s needs and requirements.
Welcome to Navinci
Navinci has a proud history as developers of the first commercial in situ Proximity Ligation Assays. The Proximity Ligation Technology can be used to monitor interactions or modifications of endogenous proteins directly in individual cells and tissues, to reveal the cellular and molecular architecture and its response to disturbances. The Naveni TM Proximity Ligation Assays are based on a new, proprietary technology providing higher sensitivity and less unspecific background than traditional Proximity Ligation Assay.
Bringing precision to spatial proteomics
Navinci is a Swedish biotech company specializing in innovative proximity ligation assay -based solutions for spatial proteomics. Our goal is to create and apply the latest technological advances in kits and services for scientists that strive to be at the forefront of research. We’re committed to meeting customer needs through products of the highest quality, performance, and reliability. Our technology enables visualization of protein-protein interactions and post-translational modifications directly in tissue and cells. And our immunooncology kits (e.g., for detection of PD1/PD-L1 interaction) provide an opportunity to identify strong drug candidates and stratify patients for immunotherapy. We use a multi-disciplinary, highly collaborative approach with a growing portfolio of partners to push the limits of proteomics research.
News
21.04.2023
Spatial Biology UK – latest innovations in spatial research & technologies
11.04.2023
Navinci Diagnostics announces the appointment of Dr Subham Basu as new Chief Business Officer
31.03.2023
Navinci at AACR – new research data and product developments
“To my impression it is a lot better than every other PLA we have done before. The negative controls are nearly blank for the first time ever. This is a huge advantage of your kit because this was the main point with which we always struggled when analyzing the assay in a quantitative way”.
Dr. Stefan Pusch,
Department of Neuropathology at Heidelberg University